Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MultiHance in Pediatric CNS MRI
NCT00323310Phase 3Terminated
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Apr 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gadobenate dimeglumine in central nervous system disease, sponsored by Bracco Diagnostics Inc. Primary endpoints: Delineation of Lesion Border (Change From Pre to Pre+Postdose) for Reader 1, Delineation of Lesion Border (Change From Pre to Pre+Postdose) for Reader 2 and 8 more. Started Apr 2006; status: terminated.
02
Drugs
gadobenate dimeglumine
03
Conditions
central nervous system disease
Beyond the preview
Go deeper on NCT00323310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323310.